Valneva SE Sponsored ADR VALN 深 沪
等待开盘 04-02 09:30:00 美东时间
6.27
+0.020
+0.32%
华盛通- 最 高6.69
- 今 开6.61
- 成交量 27.46万股
- 最 低 6.27
- 昨 收 6.25
- 总市值 5.45亿
- 52周最高 12.25
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 5.4289
- 委 比 19.39%
- 总股本 8687.65万
- 历史最高 67.84
- 量 比 1.33
- 振 幅 6.72%
- 历史最低 3.62
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨82.86%，网络齿轮通信涨14.78%
Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨82.86%；网络齿轮通信涨14.78%；BioCryst制药涨14.39%
03-24 16:03
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions.
03-23 22:35
Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Dow futures up 200 points, ClearPoint Neuro (CLPT) stock falls after wider-than-expected quarterly loss. Other stocks moving lower in pre-market.
03-18 20:02
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ:SAIL) is estimated to r...
03-18 19:11
Valneva Affirms FY2026 Sales Guidance of $180.443M-$197.906M
Valneva (NASDAQ:VALN) affirms FY2026 sales outlook from $180.443 million-$197.906 million to $180.443 million-$197.906 million.
03-18 17:13
Valneva Q4 EPS $(0.68) Misses $(0.21) Estimate, Sales $55.516M Miss $56.190M Estimate
Valneva (NASDAQ:VALN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.21) by 221.43 percent. This is a 25 percent decrease over losses of $(0.54) per share from the same
03-18 16:30
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
Valneva Posts €174.7M In Preliminary 2025 Revenues, Up From €169.6M In 2024, With €109.7M Cash; Guides 2026 Total Revenues Of €155M-€170M, Product Sales €145M-€160M, With Phase 3 Lyme Disease Data Expected In H1 2026
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product salesStrong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt
02-19 14:44
Valneva Announces U.K.'s Commission On Human Medicines Restricts People Aged 60+ From Using IXCHIQ Chikungunya Vaccine
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's single‑dose chikungunya vaccine, IXCHIQ®, the United
02-14 00:48
Valneva Steps Back From US Approval Bid For Chikungunya Vaccine
Valneva withdraws U.S. applications for its chikungunya vaccine Ixchiq after the FDA suspended the license and placed studies on hold following new reports of serious adverse events.
01-21 04:58
